Proteomic studies on apoB‐containing lipoprotein in cardiovascular research: A comprehensive review

Abstract The complexity of cardiovascular diseases (CVDs), which remains the leading cause of death worldwide, makes the current clinical pathway for cardiovascular risk assessment unsatisfactory, as there remains a substantial unexplained residual risk. Simultaneous assessment of a large number of plasma proteins may be a promising tool to further refine risk assessment, and lipoprotein‐associated proteins have the potential to fill this gap. Technical advances now allow for high‐throughput proteomic analysis in a reproducible and cost‐effective manner. Proteomics has great potential to identify and quantify hundreds of candidate marker proteins in a sample and allows the translation from isolated lipoproteins to whole plasma, thus providing an individual multiplexed proteomic fingerprint. This narrative review describes the pathophysiological roles of atherogenic apoB‐containing lipoproteins and the recent advances in their mass spectrometry‐based proteomic characterization and quantitation for better refinement of CVD risk assessment.